[HTML] frontiersin.org

[HTML][HTML] The resistance mechanisms and treatment strategies for ALK-rearranged non-small cell lung cancer

Y Pan, C Deng, Z Qiu, C Cao, F Wu - Frontiers in oncology, 2021 - frontiersin.org
Anaplastic lymphoma kinase (ALK) is a validated molecular target for non-small-cell lung
cancer (NSCLC). The use of tyrosine kinase inhibitors (TKIs) has led to significantly …
被引用次数：72 相关文章
[HTML] nih.gov

[HTML][HTML] The Resistance Mechanisms and Treatment Strategies for ALK-Rearranged Non-Small Cell Lung Cancer

Y Pan, C Deng, Z Qiu, C Cao, F Wu - Frontiers in Oncology, 2021 - ncbi.nlm.nih.gov
Anaplastic lymphoma kinase (ALK) is a validated molecular target for non-small-cell lung
cancer (NSCLC). The use of tyrosine kinase inhibitors (TKIs) has led to significantly …

The Resistance Mechanisms and Treatment Strategies for ALK-Rearranged Non-Small Cell Lung Cancer.

Y Pan, C Deng, Z Qiu, C Cao, F Wu - Frontiers in Oncology, 2021 - europepmc.org
Anaplastic lymphoma kinase (ALK) is a validated molecular target for non-small-cell lung
cancer (NSCLC). The use of tyrosine kinase inhibitors (TKIs) has led to significantly …

The Resistance Mechanisms and Treatment Strategies for ALK-Rearranged Non-Small Cell Lung Cancer

Y Pan, C Deng, Z Qiu, C Cao… - Frontiers in oncology, 2021 - pubmed.ncbi.nlm.nih.gov
Anaplastic lymphoma kinase (ALK) is a validated molecular target for non-small-cell lung
cancer (NSCLC). The use of tyrosine kinase inhibitors (TKIs) has led to significantly …
[PDF] core.ac.uk

[PDF][PDF] The Resistance Mechanisms and Treatment Strategies for ALK-Rearranged Non-Small Cell Lung Cancer. Front

Y Pan, C Deng, Z Qiu, C Cao, F Wu - Oncol, 2021 - core.ac.uk
Anaplastic lymphoma kinase (ALK) is a validated molecular target for non-small-cell lung
cancer (NSCLC). The use of tyrosine kinase inhibitors (TKIs) has led to significantly …